Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Update

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 942,551 shares, an increase of 3,584.7% from the May 31st total of 25,580 shares. Based on an average daily volume of 28,446,970 shares, the short-interest ratio is currently 0.0 days. Approximately 79.8% of the shares of the company are short sold.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC bought a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Stock Performance

Shares of NYSEAMERICAN:RGNT traded down $0.05 on Thursday, hitting $4.15. The company’s stock had a trading volume of 169,962 shares, compared to its average volume of 16,503,722. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50. The company’s 50-day moving average price is $2.79.

Wall Street Analyst Weigh In

Separately, ThinkEquity raised Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Regentis Biomaterials presently has a consensus rating of “Strong Buy”.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.